ATLANTA (November 30, 2005) - Alimera Sciences Inc., an ophthalmic pharmaceutical company, announced today that it has completed Series B financing, securing $31.8 million in venture capital. Premier venture firm Venrock Associates led the new round, and all four original Series A firms continued their investment.

ATLANTA, GA (October 3, 2005) - Alimera Sciences Inc., a dynamic ophthalmic pharmaceutical company, in collaboration with Control Delivery Systems Inc. (CDS), a leader in innovative drug delivery systems for the eye, recently initiated a Phase III clinical trial to study diabetic macular edema (DME) patients treated using Medidur™ with fluocinolone acetonide, the companies' pharmacologic treatment for DME.

ATLANTA (May 9, 2005) - Alimera Sciences Inc., a dynamic ophthalmic pharmaceutical company, today announced that its Soothe® Emollient (Lubricant) Eye Drops are now available for purchase over the Internet. To order the over-the-counter eye drops, consumers and professionals can visit www.sootheeyedrops.com or link from Alimera Sciences' home page.

ATLANTA (March 21, 2005) - Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, today announced that it will support the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) in 2005 as its first "Partner for Learning."

ATLANTA (March 7, 2005) - Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, today named Phil Tracy, J.D., chairman of the company's board of directors.

ATLANTA, GA. and WATERTOWN, MA (February 16, 2005) - Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, and Control Delivery Systems Inc. (CDS), a leader in innovative drug delivery systems for the eye, today announced a worldwide agreement to co-develop and market a new pharmacologic treatment indicated for diabetic macular edema (DME), a major cause of vision loss in people suffering from diabetic retinopathy. Alimera Sciences also has the option to develop three additional products using CDS' drug delivery technology.

ATLANTA (January 26, 2005) - Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, announced that the company was awarded the Georgia Biomedical Partnership (GBP) inaugural Deal of the Year award for its 2004 Series A financing of $26.75 million.